<code id='FB8B16B06C'></code><style id='FB8B16B06C'></style>
    • <acronym id='FB8B16B06C'></acronym>
      <center id='FB8B16B06C'><center id='FB8B16B06C'><tfoot id='FB8B16B06C'></tfoot></center><abbr id='FB8B16B06C'><dir id='FB8B16B06C'><tfoot id='FB8B16B06C'></tfoot><noframes id='FB8B16B06C'>

    • <optgroup id='FB8B16B06C'><strike id='FB8B16B06C'><sup id='FB8B16B06C'></sup></strike><code id='FB8B16B06C'></code></optgroup>
        1. <b id='FB8B16B06C'><label id='FB8B16B06C'><select id='FB8B16B06C'><dt id='FB8B16B06C'><span id='FB8B16B06C'></span></dt></select></label></b><u id='FB8B16B06C'></u>
          <i id='FB8B16B06C'><strike id='FB8B16B06C'><tt id='FB8B16B06C'><pre id='FB8B16B06C'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:fashion    Page View:5
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In